% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fazekas:282906,
      author       = {T. Fazekas and Á. D. Széles and B. Teutsch and A.
                      Csizmarik and B. Vékony and T. Kói and N. Ács and P.
                      Hegyi and B. Hadaschik$^*$ and P. Nyirády and T.
                      Szarvas$^*$},
      title        = {{P}oly ({ADP}-ribose) {P}olymerase {I}nhibitors {H}ave
                      {C}omparable {E}fficacy with {P}latinum {C}hemotherapy in
                      {P}atients with {BRCA}-positive {M}etastatic
                      {C}astration-resistant {P}rostate {C}ancer. {A} {S}ystematic
                      {R}eview and {M}eta-analysis.},
      journal      = {European urology oncology},
      volume       = {7},
      number       = {3},
      issn         = {2588-9311},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01898},
      pages        = {365-375},
      year         = {2024},
      note         = {2024 Jun;7(3):365-375},
      abstract     = {Testing for mutations in Breast Cancer Gene 1/2 (BRCA) has
                      emerged as a novel decision-making tool for clinicians.
                      Patients with metastatic castration-resistant prostate
                      cancer (mCRPC) harboring pathogenic BRCA mutations can
                      benefit from poly (ADP-ribose) polymerase inhibitor (PARPi)
                      and platinum treatments, whereas the impact of the mutation
                      on sensitivity to cabazitaxel and prostate-specific membrane
                      antigen (PSMA)-ligand therapy is currently unknown.To assess
                      the efficacy of PARPi, platinum, cabazitaxel, and
                      PSMA-ligand therapies in BRCA-positive mCRPC.Databases were
                      queried in February 2022. We performed data synthesis by
                      using both proportional and individual patient data. For
                      prostate-specific antigen (PSA) response rate $(≥50\%$
                      decrease from baseline [PSA50]) evaluation, we pooled event
                      rates with $95\%$ confidence intervals (CIs).
                      Progression-free (PFS) and overall (OS) survival analyses
                      with individual patient data were performed with the
                      mixed-effect Cox proportional hazard model and single-arm
                      random-effect analysis, providing pooled medians.We included
                      23 eligible studies with 901 BRCA-positive mCRPC patients.
                      PSA50 response rates for PARPi and platinum were $69\%$ (CI:
                      $53-82\%),$ and $74\%$ (CI: $49-90\%),$ respectively.
                      Analyses of OS data showed no difference between PARPi and
                      platinum treatments (hazard ratio: 0.86; CI: 0.49-1.52; p =
                      0.6). The single-arm OS and PFS analyses revealed
                      similarities among different PARPis; pooled PFS and OS
                      medians were 9.7 mo (CI: 8.1-12.5) and 17.4 mo (CI:
                      12.7-20.1), respectively.Our data revealed that different
                      PARPis were similarly effective in terms of PFS and OS.
                      Moreover, we found that PARPi and platinum therapy were
                      comparable in terms of PSA50 response rate and OS,
                      highlighting that platinum is a valid treatment option for
                      BRCA-positive mCRPC patients. However, prospective
                      interventional studies comparing these agents are essential
                      to provide a higher level of evidence.In this report, we
                      found that different poly (ADP-ribose) polymerase inhibitors
                      had similar efficacy, and platinum was a valid treatment
                      option in BRCA-positive metastatic castration-resistant
                      prostate cancer patients.},
      subtyp        = {Review Article},
      keywords     = {Ac-PSMA (Other) / BRCA (Other) / Cabazitaxel (Other) /
                      Carboplatin (Other) / Cisplatin (Other) / DNA repair (Other)
                      / Lu-PSMA (Other) / Metastatic castration-resistant prostate
                      cancer (Other) / Niraparib (Other) / Olaparib (Other) /
                      Prostate cancer (Other) / Prostate-specific membrane antigen
                      (Other) / Rucaparib (Other) / Talazoparib (Other) / Taxane
                      (Other) / Veliparib (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37722977},
      doi          = {10.1016/j.euo.2023.09.001},
      url          = {https://inrepo02.dkfz.de/record/282906},
}